GlassScriptPhysician profile
Meechai Tessalee
NPI 1841295193
$2,556.68
in general payments reported to CMS, 2019-2025
16 companies · $512 in 2025
The $512 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2021: $336 · 2022: $288 · 2023: $617 · 2024: $467 · 2025: $512.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,426 · Travel and Lodging: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,425.97 |
| Travel and Lodging | $169.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $610.58 | 2022-2025 | Symplicity G3, Hawkone |
| Edwards Lifesciences Corporation | $519.14 | 2019-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Shockwave Medical, INC | $351.56 | 2021-2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boston Scientific Corporation | $212.61 | 2024-2025 | Watchman Access System, Rotapro, Watchman Flx |
| Boehringer Ingelheim Pharmaceuticals, INC. | $187.41 | 2019-2023 | Jardiance |
| Amgen INC. | $186.56 | 2019-2025 | Repatha, Repatha |
| Impulse Dynamics (USA) INC. | $153.25 | 2023 | Optimizer |
| Philips North America LLC | $71.83 | 2021 | |
| Janssen Pharmaceuticals, INC | $62.49 | 2019-2024 | Xarelto |
| Novartis Pharmaceuticals Corporation | $62.13 | 2022 | |
| Abiomed | $36.79 | 2024 | |
| Cook Medical LLC | $28.67 | 2024 | Zilver Ptx |
| Abbott Laboratories | $24.04 | 2024 | Cardiomems |
| Pfizer INC. | $23.18 | 2019 | |
| Baxter Healthcare | $14.33 | 2025 | Perclot |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Meechai Tessalee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.